- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Inflammation

Inflammation is an early defense that protects our body from infection. However, ongoing or misdirected inflammation underlies many diseases.
Our researchers are revealing how inflammation is controlled, and advancing the diagnosis and treatment of inflammatory diseases.
Our inflammation research
Our researchers seek to understand how inflammation is controlled in health and disease. To do this they are investigating:
- The molecules and cells that contribute to the initiation, magnitude and resolution of inflammatory responses.
- Inflammatory pathways that are associated with disease.
- New strategies to treat harmful inflammation, and promote beneficial inflammation.
The goal of our inflammation research is to advance strategies to diagnose, treat and prevent inflammatory diseases including:
- Coeliac disease
- Inflammatory bowel disease
- Lupus
- Multiple sclerosis
- Rheumatic fever
- Rheumatoid arthritis
- Type 1 diabetes
- Infections including influenza and malaria
- Cancers associated with inflammation such as bowel cancer and stomach cancer
What is inflammation
Inflammation is the body’s natural response to infection, disease and tissue damage. Inflammation is driven by immune cells, and also serves to heighten the immune response.
Features of inflamed tissues include:
- Redness and warmth, from increased blood flow to the area.
- Swelling, from an influx of fluid.
- Pain.
- Immobility.
These symptoms of inflammation serve several important functions:
- Alerting and attracting immune cells to an area of potential infection.
- Releasing substances that help to repair damaged tissue.
- Immobilising the injured or infected tissue to reduce damage or spread of infection.
Inflammation can be acute, meaning it is rapidly resolved, or chronic, meaning it can persist for years.
What causes inflammation?
Inflammation can have a variety of triggers including:
- Tissue damage, such as a burn or cut.
- Clot formation by platelets.
- The presence of a foreign substance.
- Microbial infection.
- Some forms of cell death.
Inflammation begins with innate immune cells, such as neutrophils, being alerted to the trigger. This may be because damaged tissue has released ‘alert’ signals, or because the immune cell has detected microbial molecules such as bacterial cell wall components.
When activated, innate immune cells can immediately release a variety of inflammatory substances. These substances trigger the features of inflammation in nearby tissue, protecting the site and attracting an influx of additional immune cells. Different immune cell types, and inflammatory mediators are detected in acute and chronic inflammation.
Inflammatory mediators are typically short-lived. This serves to limit the duration of an inflammatory response. As soon as the trigger is removed, inflammation will normally diminish, preventing tissue damage.
Inflammation and cell death
Our research into how cells die has revealed that many of the molecules contributing to cell death have dual roles in inflammation, or are closely related to molecules functioning in inflammatory pathways.
Some types of cell death trigger inflammation. This ensures that the abnormal death of cells alerts immune cells to a potentially dangerous situation.
Beneficial inflammation
Inflammation is an important component of the innate immune response, which is the body’s first line of defense against infection. Inflammatory mediators enhance the responses of immune cells to potential infections, by:
- Increasing blood flow and movement of immune cells into the inflamed tissue
- Stimulating immune cells, such as triggering macrophages to be more likely to engulf nearby substances.
- Stimulating production of new immune cells through the release of colony stimulating factors
Inflammation is important for the generation of protective immunological memory. This ensures that repeat exposures to a microbe are rapidly dealt with by established immune cells that recognise the infectious agent.
Most vaccines include substances that trigger inflammation. These contribute to better immune responses, and longer-lasting immune protection.
Inflammatory diseases
Excessive or ongoing inflammation can cause pain and tissue damage, and prevent the normal functioning of the body’s organs.
Short-term, acute inflammation can be responsible for many of the symptoms of infections. These symptoms, such as fever, tend to assist the immune clearance of infection. Excessive or misplaced acute inflammation can cause severe illness or death.
Chronic inflammation is also associated with many diseases. Approximately one in three Australians has a chronic inflammatory disease, such as rheumatoid arthritis. These diseases place a significant social and economic burden on the community.
Chronic inflammation is triggered by ongoing immune responses. These immune responses can be against:
- A chronic infection that is not cleared. Chronic inflammation to the hepatitis B virus contributes to liver damage.
- The body’s own tissue, such as joint tissue in rheumatoid arthritis.
In some conditions, such as rheumatic fever, inflammation begins in response to an infection by Streptococcus bacteria, but is redirected later to heart tissue, causing damage.
Treating inflammation
In many inflammatory diseases, symptoms can be greatly reduced in the short term by appropriate treatment. These include:
- Corticosteroids that reduce immune cell function.
- ‘Non-steroidal’ anti-inflammatory medications that interfere with key molecules or cells contributing to the symptoms of inflammation.
- Targeted therapies that specifically inhibit the molecules that underpin inflammation or immune cell function. These are showing great promise in improving the outlook for people with inflammatory diseases.
Compressing, immobilising and cooling the inflamed area can also improve the symptoms of inflammation, but do not eliminate the underlying cause of the inflammation.
Researchers:
WEHI.TV animation: how insulin is normally produced in the body and how its production is destroyed in type 1 diabetes.
Dr Tracy Putoczki presents her research findings into targeting cytokines in inflammatory diseases with a focus on Interkeukin-11.
Our research has revealed the structure of a protein that triggers a form of programmed cell death called necroptosis
Our public forum explained how research into arthritis is leading to better treatments.
While most proteins were readily consumed, some people’s immune systems struggled to tolerate others.